GlaxoSmithKline (GSK) plc today launched Target the Future, an international, multi-year initiative dedicated to advancing innovation and addressing key needs in the multiple myeloma community. The programme will provide education on progress in the field of multiple myeloma, identify key challenges the community faces, and facilitate solutions to help create a better future for patients, their caregivers and loved ones.
GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community
December 2, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022